Denosumab Fracture Data Positive In Prostate Cancer Patients
This article was originally published in The Pink Sheet Daily
Amgen’s twice-yearly injection still has high bar to pass on fracture risk reduction in postmenopausal women with osteoporosis.
You may also be interested in...
With ESA safety in the spotlight, Amgen faced its toughest year, CEO Sharer says.
Firm plans to file BLA in late 2008, early 2009 for post-menopausal osteoporosis and treatment induced osteopenia.
The US FDA appears to have concerns about the device used to administer the vaccine.